# NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

> **NCT02434081** · PHASE2 · COMPLETED · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 94 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage III

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02434081
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-25
- **Primary completion:** 2020-02-29
- **Final completion:** 2020-03-31
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2022-08-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02434081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02434081, "NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02434081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*